SHENZHEN, China, Jan. 21 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is set to appoint Mr. Terry Yuan as its new CEO. Terry is the current President and CEO of Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope), www.mellowhope.com, a company targeted for a merger with HTDS. (See previous news Jan 14 2009). The company will complete the filings on Pink Sheets shortly.
Mr. Terry Yuan will also maintain the same President and CEO position with Mellow Hope. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is the biggest exporter of Biological Vaccines in China. In cooperation with Institutes of Medical Biology and Pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy.
Mr. Terry Yuan said, "We continue our merger discussions with Hard To Treat Diseases. At present all systems appear to be a go. I know that Andrea Zecevic, HTDS Chief Project Scientist and Director, R&D has been going over all the documents we provided and is receiving feedbacks from the doctors team in Serbia and completing organizing and indexing all submissions. She has done an extraordinary job in putting the whole team together."
Mr. Keith Roberts outgoing and interim CEO of Hard To Treat Diseases said "We wish to welcome Mr Terry Yuan aboard HTDS. Save for some highly unlikely and unforeseen obstruction which may arise, at this point I can safely say nothing appears to be in the way of this merger. I concur with Terry that on our end it also appears all systems are a go for this merger. The target date is shaping out to be the first part of February. Assuming all goes well the "signing ceremony" will follow in China. My understanding is that the event will be covered by the Chinese media TV, and news print and medical industry journals in China."
Mr. Keith Roberts will retain the position of the CFO with the company after the resignation as a CEO.
The will provide additional updates on developments as they unfold.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at firstname.lastname@example.org; For any corporate matters the readers should contact the company directly at email@example.com
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved